MIA leads world-class skin tumour pathology conference
14 February 2020
World-leading skin cancer experts, headed by Co-Medical Director of Melanoma Institute Australia Professor Richard Scolyer, will converge on The University of Sydney’s Charles Perkins Centre this weekend to instruct a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
Attendees will also hear from two international melanoma experts across the breadth of the program - Professor Klaus Busam, Director of Dermatopathology at Memorial Sloan Kettering Cancer Centre, New York, and Professor Pedram Gerami, Professor of Dermatology at Northwestern University, Illinois.
MIA clinicians and researchers will provide a wealth of home-grown expertise with talks from epidemiologist Professor Anne Cust, pathologists Dr Peter Ferguson and Dr Robert Rawson, world-renowned melanoma and surgical oncologist Professor John Thompson, and Co-Medical Director of MIA Professor Georgina Long.
The course aims to provide international attendees with the latest in skin tumour pathology, discussing current best practice and new tests, along with highlighting the integration of clinical and genomic information for diagnosis, prognosis and treatment selection. The course will end with detailed examination of high-value educational cases to consolidate two days worth of world-class learnings.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.